CYP19A1 and breast carcinoma: Similar studies with ribociclib (MONALEESA-2) and abemaciclib (MONARCH 3; combined with a nonsteroidal aromatase inhibitor), both of which were combined with letrozole as initial therapy for advanced breast cancer, reported median PFS of 25.3 and 28.2 months, respectively (22–24).